Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 2349
“I Was Prepared for the Other Side Effects; I Wasn’t Prepared for This One.”: A Qualitative Study of the Patients’ Experience of Inflammatory Arthritis Due to Immune Checkpoint Inhibitor Therapy for Cancer
Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives- 9:00AM-11:00AM
-
Abstract Number: 2720
30-Day Hospital Readmission for Granulomatosis with Polyangiitis: Analysis from National Readmission Database
Vasculitis – ANCA-Associated Poster II- 9:00AM-11:00AM
-
Abstract Number: 2086
4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 2171
A 5-Year National Trend in Acute Myocardial Infarctionamong Hospitalized Patients with Psoriatic Arthritis: Data from National Inpatient Sample
Health Services Research Poster III – ACR/ARHP- 9:00AM-11:00AM
-
Abstract Number: 2757
A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: 2152
A Comparison of the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics Classification (SLICC) Criteria to Detect Patients with Systemic Lupus Erythematosus (SLE) in Electronic Health Record (EHR) Data
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2439
A Description of Contraception Practices in the Ohio State University Lupus Cohort
Reproductive Issues in Rheumatic Disorders Poster- 9:00AM-11:00AM
-
Abstract Number: 2508
A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2341
A Link between Quality of Patient–Rheumatologist Communication and Patient Healthcare Needs in Psoriatic Arthritis: An Online Survey of US-Based Patients and Rheumatologists
Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives- 9:00AM-11:00AM
-
Abstract Number: 2762
A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: 2146
A Meta-Analysis of the Prevalence and Risk Factors for Retinal Toxicity in Rheumatologic Patients on Hydroxychloroquine Therapy
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 1981
A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 2504
A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2756
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial